New Chief Commercial Officer joins as company surpasses 10,000 canine cancer samples and expands lab capacity to scale veterinary and human precision oncology services

ImpriMed, a Silicon Valley-based pioneer in AI-driven precision medicine for oncology, today announced key milestones signaling its next phase of growth. The company has appointed Valerie Goodwin-Adams as Chief Commercial Officer (CCO) to spearhead its commercial expansion, leveraging her extensive experience in scaling operations at high-growth life science firms. This momentum is further reflected in ImpriMed’s move to a new state-of-the-art laboratory and offices in Palo Alto and the successful processing of its 10,000th live canine cancer cell sample, underscoring accelerating demand for pharmaceutical and human precision medicine services.

Strategic Leadership Appointment

As CCO, Goodwin-Adams brings a proven track record of driving revenue, market expansion, and successful exits at high-growth life science companies. At ImpriMed, she will oversee global sales, marketing, and commercial operations, with a focus on strengthening the company’s presence in the oncology and pharmaceutical markets and guiding its entry into human precision medicine.

Her appointment follows impactful roles at both AllCells and Abaxis. At AllCells, Goodwin-Adams directed a company-wide commercial transformation that successfully led to its acquisition by Discovery Life Sciences. While at Abaxis, she served as Senior Director of Global Revenue and oversaw global marketing, inside sales, and product management until its acquisition by Zoetis, a leading global animal health company.

“ImpriMed’s groundbreaking fusion of ex vivo drug sensitivity testing with AI has already transformed oncology care in veterinary medicine,” said Valerie Goodwin-Adams, CCO of ImpriMed. “Joining at this stage of rapid growth is truly invigorating. I’m eager to help drive our innovative approach into new frontiers across both the pharmaceutical and human healthcare sectors.”

Expanding Footprint and Capabilities

ImpriMed has relocated to a new facility in Palo Alto. Purpose-built to accelerate sample throughput and advance cutting-edge R&D, the new laboratory provides state-of-the-art infrastructure essential for the company’s continued growth. In addition to expanded space for high-throughput technologies, the facility features dedicated rooms for specialized functions, including management of human primary cell specimens, veterinary primary cell processing, advanced microscopy imaging for digital cytology, and sterilization of key instruments.

The move comes as ImpriMed celebrates the processing of its 10,000th canine live cancer cell sample, a milestone that reflects the growing demand in veterinary oncology, as well as its readiness to commercialize human services and products in 2026. With its expanded lab, ImpriMed is preparing for CLIA certification and scaling its CRO services for pharmaceutical partners. These services include pre-clinical drug candidate screening on patients’ live cells, responder patient group profiling, and identification of synergistic drug combinations, leveraging its proprietary xCellSense^® platform.

“As ImpriMed enters its next phase of growth, Valerie’s expertise in scaling commercial organizations in both animal and human markets will be instrumental to our success,” said Dr. Sungwon Lim, Co-Founder and CEO of ImpriMed. “Her proven leadership comes at a pivotal time as we broaden our portfolio, driving advances in veterinary oncology while extending our reach into human precision medicine.”

About ImpriMed

ImpriMed, founded in 2017 in Silicon Valley, is an AI-powered precision medicine company revolutionizing cancer treatment. The company’s proprietary technology integrates live-cell drug sensitivity assays with advanced machine learning to provide personalized predictions of cancer treatment outcomes, helping reduce costs, enhance efficacy, and improve the quality of life for patients. Trusted by veterinary oncologists across the U.S., ImpriMed has processed more than 10,000 patient samples and is now expanding its services to pharmaceutical companies and human oncology. For more information, visit www.imprimedicine.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251014624128/en/

“As ImpriMed enters its next phase of growth, Valerie’s expertise in scaling commercial organizations in both animal and human markets will be instrumental to our success,” said Dr. Sungwon Lim, Co-Founder and CEO of ImpriMed.